Candor Therapeutics Inc. is pursuing a $750,000 exempt securities offering under a Simple Agreement for Future Equity, with $50,000 sold so far. Investors can see that $700,000 of the stated offering amount remains available, providing the clearest disclosed measure of the financing still to be completed.

Key Highlights

  • The transaction is structured as a Simple Agreement for Future Equity.
  • The notice identifies $700,000 as the remaining portion of the offering.
  • Ramkumar Mandalam is listed as an executive officer and Mohan Srinivasan as a director.

Offering Overview

Candor Therapeutics Inc. is seeking $750,000 through an exempt securities offering, according to the notice described in the article. The disclosed transaction records $50,000 as already sold and identifies $700,000 as the portion of the stated offering amount that remains available.

The offering is presented as a financing by Candor Therapeutics, a biotechnology company organized as a Delaware corporation.

Future Equity Agreement

The transaction uses a Simple Agreement for Future Equity, which is the agreement identified in the notice as the instrument for the offering. The article presents the future equity agreement as the structure associated with both the amount already sold and the amount still available under the stated offering.

The disclosed figures therefore comprise the full $750,000 offering amount, the $50,000 already sold, and the remaining $700,000. Those amounts are stated together in the notice and in the article’s description of the offering terms.

Issuer Identification

The issuer is identified as Candor Therapeutics Inc., a Delaware corporation based at 710 Lakeway Drive, Suite 200, Sunnyvale, California 94085. The Sunnyvale address is the company address provided in the notice and is also associated with the individuals named in the filing.

Candor Therapeutics identifies its industry as biotechnology.

Offering and Signature Dates

The offering is marked with an August 17, 2026 date. Separately, the document carries a signature dated August 27, 2026, making those the two dates identified in the article’s account of the notice.

The article distinguishes the date marked on the offering from the later date appearing with the signature. Both dates are included as part of the disclosed filing information, without changing the stated offering amount or the amount already sold.

Executive Officer and Director

Ramkumar Mandalam is identified as an executive officer and director of Candor Therapeutics. Mohan Srinivasan is listed as a director, and both individuals are associated with the company’s Sunnyvale address.

The notice names these individuals in connection with the issuer and its Leadership information.

Proceeds and Compensation

The notice states that officers, directors, and promoters will receive no proceeds from the offering beyond salaries and other compensation and benefits. This disclosure addresses the treatment of those groups while the company seeks the stated $750,000 through the exempt securities offering.

Candor Therapeutics therefore identifies no offering proceeds for those individuals apart from the salaries, compensation, and benefits described in the notice. The article provides no additional allocation of proceeds and no other use of the offering amount beyond the disclosed terms.

Source(s)

  • https://www.sec.gov/Archives/edgar/data/2152199/000215219926000001/primary_doc.xml